Who Supplies Ibrutinib to India from BRAZIL

To import finished pharmaceutical formulations containing Ibrutinib into India, the foreign manufacturer must obtain an Importer-Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT). The product must be registered with the Central Drugs Standard Control Organisation (CDSCO) by submitting Form 40/41, which includes detailed product information, manufacturing licenses, and stability data. The importer must also obtain a No Objection Certificate (NOC) from the CDSCO. The registration process typically takes 6–12 months, depending on the completeness of the application and regulatory reviews. For Ibrutinib formulations under HS Code 30049099, the importer must provide a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data demonstrating compliance with Indian Pharmacopoeia standards. Additionally, the importer must obtain a Drug Import License from the CDSCO, which requires submission of Form 41 and other supporting documents. The timeline for obtaining the import drug registration can vary but generally ranges from 6 to 12 months, depending on the completeness of the application and regulatory reviews.

Upon arrival in India, finished pharmaceutical formulations containing Ibrutinib are subject to quality testing by CDSCO-approved laboratories. Each batch must be accompanied by a Certificate of Analysis (CoA) issued by the manufacturer, detailing the product's specifications and compliance with Indian Pharmacopoeia standards. Stability data, including studies conducted under ICH Zone IV conditions, must be provided to demonstrate the product's shelf-life and storage requirements. Port inspection by customs drug inspectors is mandatory to verify the authenticity of the product and ensure compliance with Indian regulations. If a batch fails quality testing, it may be rejected, destroyed, or re-exported, depending on the severity of the non-compliance.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The Production Linked Incentive (PLI) scheme, introduced to promote domestic manufacturing, has led to increased scrutiny of imported formulations, including those containing Ibrutinib. Bilateral agreements between India and Brazil have facilitated smoother trade relations, but importers must still adhere to stringent regulatory requirements. The CDSCO has also streamlined the registration process for certain formulations, reducing approval timelines for products with established safety and efficacy profiles.

India imports finished Ibrutinib formulations primarily due to the high demand for patented and branded products that are not manufactured domestically. Specific dosage forms, such as oral tablets and intravenous injections, are often sourced from international markets to meet patient needs. Domestic capacity for producing Ibrutinib formulations is limited, leading to a reliance on imports to fulfill market demand. The market size for Ibrutinib formulations in India is substantial, with a growing number of patients requiring treatment for various cancers.

India sources finished Ibrutinib formulations from Brazil due to the competitive advantages offered by Brazilian manufacturers, including compliance with international quality standards and the ability to supply specialized dosage forms not readily available domestically. Brazil's share in India's Ibrutinib import market is significant, with Brazilian suppliers accounting for a notable portion of the total imports. Other suppliers, such as China, Germany, and the United States, also contribute to the market, but Brazil's unique advantages make it a preferred source for certain formulations.

India imports finished Ibrutinib formulations from Brazil due to the high quality and compliance with international standards offered by Brazilian manufacturers. Brazil provides specialized dosage forms and formulations that are not readily available domestically, fulfilling specific patient needs. The strategic sourcing from Brazil ensures a reliable supply of quality Ibrutinib formulations to meet the growing demand in India.

When compared to other origins such as China, the European Union, and the United States, Brazil offers competitive pricing and high-quality products. Brazilian manufacturers adhere to stringent quality control measures and international standards, ensuring the safety and efficacy of their products. The reliability and consistency of supply from Brazil make it a preferred choice for Indian importers seeking quality Ibrutinib formulations.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider dual-sourcing strategies, maintain adequate inventory levels, and establish robust quality assurance processes. Regular communication with suppliers and monitoring of regulatory developments are essential to ensure a stable supply chain.

1. 1Engage in dual-sourcing to reduce dependency on a single supplier.
2. 2Maintain a safety stock to buffer against supply chain disruptions.